Technology
Tech Titans Tumble
May 30, 2025
Tesla says its robotaxi dream is rolling out in Austin — well, kind of. The pilot program includes about a dozen cars, operated remotely, and limited to invite-only riders inside select zones. Not exactly the full autonomous revolution we were promised, but it’s a start (or a PR push).
On Wall Street, the markets continued to show resilience despite Moody’s recent Treasury downgrade and fresh trade jitters out of China. Investors quickly bought the dip, turning a 1% morning drop into a modest gain by day’s end. The S&P 500 and Nasdaq both closed slightly up, while the Russell 2000 slipped. It's the sixth straight win for the S&P — and yet, under the surface, analysts are mostly pressing pause on big predictions.
Earnings momentum has slowed to a crawl, but at least the bleeding has stopped. For months, Wall Street has been revising earnings forecasts downward as companies brace for tariff fallout and shifting global policy. But this week? No real changes. The market may be waiting for fresh economic data before making another move.
Despite the lack of movement, Q1 earnings have been surprisingly strong. Company guidance, more often than not, helped stabilize expectations instead of worsening them. For now, analysts are holding their red pens until further notice — but any shock, whether from policy or performance, could flip the script fast.
Presented by Turn Therapeutics
When faced with a deadly infection boasting a 70% fatality rate and no existing cure, Bradley Burnam did what most wouldn’t dare—he created the solution himself. Enter Hexagen: a groundbreaking formula that Burnam personally shepherded through the FDA clearance process for just $24,000. But he didn’t stop there. Building on this success, Burnam expanded the technology, secured two additional FDA clearances, and founded a company that’s rewriting the rules on self-made medical innovation: Turn Therapeutics.
Hexagen isn’t just breaking barriers; it’s healing them. Cleared for acute wound care and atopic dermatitis, this powerhouse formula is now on the brink of a bigger leap. Turn, the company behind Hexagen, is paving the way to expand its applications, proving there’s much more to its potential than meets the eye.
Turn just locked in a game-changing commitment—up to $75M in investment from GEM Global Yield Fund. This private equity boost is tied to the company’s plans to go public, setting the stage for Turn to make bold moves in the market spotlight..2
Turn is rolling out institutional, accredited, and unaccredited investors to participate in their current crowdfunding campaign — but only until January 2025.3
Retail traders may have flirted with UnitedHealth, but the romance appears to be over. After a surge of interest sent the stock rallying 17% off multiyear lows and lit up Reddit threads and options markets, the momentum is already cooling. Interactive Brokers data shows a sharp drop in net buying activity over the past five days, suggesting many traders are cashing out — whether for gains or to cut losses. The initial excitement has faded, and though UNH pared early losses after a dip, it looks like retail’s brief affair with the healthcare giant isn’t turning into a long-term commitment.
Elsewhere, President Trump told Walmart to “eat the tariffs” — but with thin margins, the retailer might not have much room to chew. Nvidia is partnering with Taiwan to launch its first AI supercomputer. And in a headline you didn’t expect today: 23andMe just sold a massive trove of DNA data to Regeneron in a $256 million deal. Meanwhile, if your dream vacation was a $600K trip to space… better start saving more — prices are heading up.
Presented by Atombeam
Big tech, small data… Why are industry leaders like NVIDIA, Intel and Ericsson partnering with Atombeam?1 It’s the company reimagining machine communication — and potentially the future of big tech. That’s thanks to Neurpac, Atombeam’s patented software technology that can reduce the size of low-entropy data by an average of 75%.
Lightning fast… Neurpac enables 2-4x more data to be sent faster and more securely over existing networks—no hardware upgrades — just smart, AI-powered software.
To the moon and back… The U.S Space Force and U.S. Air Force have already been on Atombeam’s customer books — and the company’s potential market is still gaining ground. Atombeam is in discussions with multiple companies, ranging from a major packaging brand to an EV enterprise.
$16M has already been invested into the company. You can invest before the round closes in 29 days.2
1 The partnership relationship varies between companies and can include the following: inclusion on a preferred vendor list, invitations to participate in certain forums; listed on the other company's website, and introduction and networking opportunities.
Advertiser's disclosures:
¹ The Company's Formula (Gx-03/Hexagen/Atopx) Has Received 510k Marketing Approval As A Medical Device Indicated For The Management Of Symptoms Related To Atopic Dermatitis/Eczema. The Formula Has Not Received Approval As A Drug For The Treatment Of Eczema Or Onychomycosis.
² A plan to IPO is no guarantee that an actual IPO will occur.
³ Please read the offering circular and related risks at StartEngine’s Turn Therapeutics webpage. This is a paid advertisement for Turn Therapeutics Regulation CF Offering. This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC.
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.
